Filter
66
Filtered Results: 66
Text search:
Drugs
for
Neglected
Diseases
initiative
DNDi
Featured
Recommendations
7
New Publications
6
Language
Document type
Studies & Reports
24
No document type
14
Strategic & Response Plan
6
Manuals
5
Resource Platforms
5
Guidelines
3
Videos
3
Fact sheets
3
Infographics
2
Situation Updates
1
Countries / Regions
Global
10
Latin America and the Carribbean
5
Ethiopia
3
Colombia
3
Africa
3
Kenya
2
East and Southern Africa
2
West and Central Africa
2
Southern Africa
2
Uganda
1
India
1
Bangladesh
1
Brazil
1
Asia
1
Authors & Publishers
Publication Years
Category
Countries
13
Clinical Guidelines
9
Pharmacy & Technologies
3
Public Health
1
Toolboxes
NTDs
42
HIV
3
Global Health Education
2
COVID-19
2
Pharmacy
2
TB
1
AMR
1
Health Financing Toolbox
1
NCDs
1
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease
(CD). T. cruzi is transmitted by triatomine insects, congenitally, through uncontrolled blood donations and organ transplants,
and via co...
Not long ago, on the occasion of the 100th anniversary of the discovery of Chagas disease, several campaigns denounced the scant progress has been made in diffrent spheres- medical, scientific and politcal- but major challanges still remain. This is...
Over 6 million people worldwide are infected with Trypanosoma cruzi, the protozoan that causes Chagas disease. Endemic in 21 Latin American countries, the disease can be transmitted by vector insect...
J Glob Health Sci. 2020 Jun;2(1):e3. A group of enzootic and zoonotic protozoan infections, the leishmaniases constitute among the most severely neglected tropical diseases (NTDs) and are found in a...
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of ...
The objectives of the meeting were:
1. To step up the commitment of national authorities and technical and financial partners toWHO’s elimination objective for g-HAT.
2. To share achievements, challenges and views on the elimination goal among c...
On 9 February 2021, a first webinar entitled “Expanding our understanding of Post COVID-19 condition” was held under the auspices of WHO and in consultation with the International Severe Acute Respiratory and Emerging Infection Consortium(ISARIC), Global Research Collaboration ... Infectious Disease Preparedness (GloPID-R), National Institutes of Health/National Institute of Allergy and Infectious Diseases(NIH/NIAID), Long Covid SOS and patient representatives.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has impr...
Lessons from the STEP-TB Project.
Accessed November 2017.
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species ... which there is strong evidence for the efficacy of miltefosine has increased from two to four; and the recommendation for intralesional antimonials is now strong. For mucosal leishmaniasis there is now a strong recommendation for use of pentavalent antimonials with or without oral pentoxifylline. For visceral leishmaniasis, the strong recommendations for use of pentavalent antimonials and amphotericin B deoxycholate are now conditional.
Meeting Report
27–30 June 2017 Manila, Philippines
Technology landscape
Rreport of a WHO Consultative Meeting Kolkata India 2012
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the vari...
The growing challenges for people in low and middle-income countries to access new medicines.
Analysis 58
The present information document supplements the WHO audited financial statements for 2018. It contains information on WHO's voluntary contributions by fund and by contributor in the year 2018.
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...
